RAET1G Antibody (6D10): sc-53134

RAET1G Antibody (6D10) is a mouse monoclonal IgM antibody that detects RAET1G of human origin by immunofluorescence (IF). Anti-RAET1G antibody (6D10) is available as the non-conjugated form. RAET1G, also known as retinoic acid early transcript 1G, is a 334 amino acid single-pass type I membrane protein that plays a crucial role in immune response by acting as a ligand for the NKG2-D receptor, which is essential for mediating natural killer (NK) cell cytotoxicity. This interaction is particularly important in tumor surveillance, as RAET1G is highly expressed in colon tissues and various tumor cell lines, enabling NK cells to recognize and eliminate malignant cells. RAET1G differs from other RAET1 proteins by possessing type I membrane-spanning sequences at its C terminus instead of glycosylphosphatidylinositol anchor sequences, which influences localization and function within the immune system. The RAET1G gene, located on human chromosome 6q25.1, contains five exons and spans approximately 6 kb, existing in two alternatively spliced isoforms. With significant similarity to ULBP2 and ability to bind to the cytomegalovirus glycoprotein ULBP, RAET1G is a vital component in the regulation of immune responses, making RAET1G an important target for research in cancer immunology and therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

RAET1G Antibody (6D10) References:

1. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.  |  Cosman, D., et al. 2001. Immunity. 14: 123-33. PMID: 11239445
2. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells.  |  Kubin, M., et al. 2001. Eur J Immunol. 31: 1428-37. PMID: 11465099
3. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.  |  Steinle, A., et al. 2001. Immunogenetics. 53: 279-87. PMID: 11491531
4. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.  |  Sutherland, CL., et al. 2002. J Immunol. 168: 671-9. PMID: 11777960
5. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D.  |  Bacon, L., et al. 2004. J Immunol. 173: 1078-84. PMID: 15240696
6. Cellular expression, trafficking, and function of two isoforms of human ULBP5/RAET1G.  |  Eagle, RA., et al. 2009. PLoS One. 4: e4503. PMID: 19223974
7. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.  |  Wittenbrink, M., et al. 2009. Eur J Immunol. 39: 1642-51. PMID: 19424970
8. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting.  |  McGilvray, RW., et al. 2009. Clin Cancer Res. 15: 6993-7002. PMID: 19861434
9. Post-translational modification of the NKG2D ligand RAET1G leads to cell surface expression of a glycosylphosphatidylinositol-linked isoform.  |  Ohashi, M., et al. 2010. J Biol Chem. 285: 16408-15. PMID: 20304922
10. MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer.  |  Cho, H., et al. 2014. BMC Cancer. 14: 957. PMID: 25510288
11. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.  |  Shin, S., et al. 2017. Cancer Genomics Proteomics. 14: 349-362. PMID: 28871002
12. Chemotherapy-induced fatigue is associated with changes in gene expression in the peripheral blood mononuclear cell fraction of patients with locoregional breast cancer.  |  de Alcântara, BBR., et al. 2019. Support Care Cancer. 27: 2479-2486. PMID: 30382394

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-RAET1G Antibody (6D10) has 5 citations in a variety of scientific publications.

Primary antibodies like Anti-RAET1G Antibody (6D10) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

RAET1G Antibody (6D10) Specifications

Alternate Product Name: RAET1G

Product Clone Name: 6D10

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM

Amino Acids:

Epitope Target: RAET1G

Epitope Species: human

Product Reactivity/Detection: RAET1G

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: IF

Vialing Information: Each vial contains 200 µg IgM in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 5 citations in various scientific publications

Available Conjugates/Forms for RAET1G Antibody (6D10): L: Azide-Free